NCT01085214 · OUTCOME

Incidence of Toxicity That May Be Treatment Emergent

AZD6244 (Selumetinib) in Treating Patients With Multiple Myeloma · Source last updated 2015-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: 1 year, 11 months

What was measured

Participants with Grade 3, 4, and 5 toxicities possibly, probably, or definitely related to study treatment. Toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE).

Analysis population: All participants who received study treatment

Groups in this outcome

AZD6244 (Selumetinib) Treatment

Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
AZD6244 (Selumetinib) Treatment	36

Reported measurements

Hematologic - Any Grade 3

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	6	Not reported	Not reported	Not reported	Not reported

Hematologic - Any Grade 4

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	2	Not reported	Not reported	Not reported	Not reported

Hematologic - Any Grade 5

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	0	Not reported	Not reported	Not reported	Not reported

Non-Hematologic - Any Grade 3

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	14	Not reported	Not reported	Not reported	Not reported

Non-Hematologic - Any Grade 4

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	1	Not reported	Not reported	Not reported	Not reported

Non-Hematologic - Any Grade 5

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
AZD6244 (Selumetinib) Treatment	3	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
6
title
Hematologic - Any Grade 3
categories
measurements
group Id
OG000
value
2
title
Hematologic - Any Grade 4
categories
measurements
group Id
OG000
value
0
title
Hematologic - Any Grade 5
categories
measurements
group Id
OG000
value
14
title
Non-Hematologic - Any Grade 3
categories
measurements
group Id
OG000
value
1
title
Non-Hematologic - Any Grade 4
categories
measurements
group Id
OG000
value
3
title
Non-Hematologic - Any Grade 5

denoms

counts
group Id
OG000
value
36
units
Participants

description

groups

description
Participants received AZD6244 (Selumetinib) orally (PO) twice a day (BID) on days 1-28. Courses repeated every 28 days in the absence of disease progression or unacceptable toxicity.
id
OG000
title
AZD6244 (Selumetinib) Treatment

param Type

NUMBER

population Description

All participants who received study treatment

reporting Status

POSTED

time Frame

1 year, 11 months

title

Incidence of Toxicity That May Be Treatment Emergent

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice